Clinical Findings and Treatment of Megaloblastic Anemia

Clinical Findings

Macrocytic anemia (MCV > 100 fL) with distinctive morphologic abnormalities in red cell precursors in bone marrow is a characteristic of megaloblastic anemia, according to the National Comprehensive Cancer Network 1
Fatigue and weakness that interferes with normal functioning and is not proportional to recent activity are common symptoms of megaloblastic anemia, as reported by the National Comprehensive Cancer Network 1
Exercise dyspnea, syncope, headache, vertigo, and chest pain are possible systemic symptoms of megaloblastic anemia, as noted by the National Comprehensive Cancer Network 1
Abnormal menstruation in female patients can occur in megaloblastic anemia, as observed by the National Comprehensive Cancer Network 1
Pallor of skin and mucous membranes is a physical finding in patients with megaloblastic anemia, according to the National Comprehensive Cancer Network 1

A complete blood count showing macrocytic anemia (MCV > 100 fL) is a key diagnostic test for megaloblastic anemia, as recommended by the National Comprehensive Cancer Network 1
Reticulocyte count (typically low, indicating decreased RBC production) is an important laboratory test in the diagnosis of megaloblastic anemia, as noted by the National Comprehensive Cancer Network 1
Other causes of macrocytosis, such as alcoholism, myelodysplastic syndromes (MDS), and certain drugs (hydroxyurea, diphenytoin), should be considered in the differential diagnosis of megaloblastic anemia, as suggested by the National Comprehensive Cancer Network 1
Non-megaloblastic causes of anemia, including hemorrhage, hemolysis, bone marrow failure, and anemia of chronic inflammation, should also be considered in the differential diagnosis, as recommended by the National Comprehensive Cancer Network 1

Parenteral B12 replacement for severe deficiency or neurological symptoms is a recommended treatment approach, with initial dosing of 1000 μg intramuscularly daily for 1 week, then weekly for 1 month, then monthly for life in pernicious anemia, as suggested by the National Comprehensive Cancer Network 2
In cases where megaloblastic anemia is related to myelodysplastic syndromes, specific treatment protocols for MDS may be required, as noted by the National Comprehensive Cancer Network 2, 3